Dr. Martin on the 2-Year Follow-Up Results of the CARTITUDE-1 Study in R/R Multiple Myeloma
December 14th 2021Thomas G. Martin, MD, discusses the 2-year follow-up data of the phase 1/2 CARTITUDE-1 study in relapsed/refractory multiple myeloma, that were presented during the 2021 ASH Annual Meeting & Exposition.
Frontline Cabozantinib Plus Atezolizumab Shows Favorable Survival in Advanced HCC
November 26th 2021The combination of cabozantinib and atezolizumab led to a statistically significant improvement in progression-free survival and a numerical improvement in overall survival vs sorafenib as frontline treatment in patients with advanced hepatocellular carcinoma, according to findings from the first planned analysis of the phase 3 COSMIC-312 trial.
Investigators Aim to Identify New Treatment Targets with Cancer Cell Map Initiative
The Cancer Cell Map Initiative, developed by investigators at the University of California San Francisco and the University of California San Diego, has successfully charted how hundreds of genetic mutations involved in breast cancer and cancers of the head and neck affect the activity of proteins that ultimately lead to disease.
Frontline Pembrolizumab/Chemo Represents New Standard in Metastatic TNBC With PD-L1 CPS ≥10
Hope S. Rugo, MD, discusses the final data from the phase 3 KEYNOTE-355 trial with pembrolizumab plus chemotherapy in patients with metastatic TNBC and the clinical impact on the treatment paradigm.
Investigators Look to Overcome Resistance in Advanced HCC With Triplet Combinations
September 5th 2021Triplet regimens leveraging novel agents targeted at overcoming mechanisms of resistance in combination with immune checkpoint inhibitors and anti-angiogenic therapies represent the next frontier in hepatocellular carcinoma.
Nab-paclitaxel Plus Gemcitabine Boosts Survival for Pancreatic Cancer in 5-year Follow-Up
July 29th 2021Updated overall survival data from the APACT trial suggest improved outcomes for patients with resected pancreatic cancer who receive adjuvant nab-paclitaxel plus gemcitabine despite missing the primary end point in earlier analysis.
Ficlatuzumab Plus Chemotherapy Produces Promising Preliminary Clinical Activity in High-Risk AML
July 21st 2021The investigational therapy ficlatuzumab in combination with cytarabine demonstrated encouraging clinical efficacy with favorable tolerability when used as a treatment in patients with high-risk acute myeloid leukemia.
Adoption of BCMA-Directed CAR T-Cell Therapy Kickstarts A New Era in Multiple Myeloma
May 10th 2021Nina Shah, MD, discusses the newfound role of BCMA-directed CAR T-cell therapies in multiple myeloma, how the field may select between ide-cel and cilta-cel if the latter is approved, and novel cellular therapies in clinical development.
Dr. Shah on the Potential Rationale for Selecting Ide-Cel Vs Cilta-Cel In Multiple Myeloma
March 26th 2021Nina Shah, MD, discusses the potential rationale for selecting between the investigational CAR T-cell therapies idecabtagene vicleucel and ciltacabtagene autoleucel in relapsed/refractory multiple myeloma.
Margetuximab Approval Augments Emerging Treatment Choices in Breast Cancer
March 8th 2021Margetuximab represents an effective new therapeutic option that can be combined safely with a chemotherapy drug of choice for patients with metastatic HER2-positive breast cancer who have undergone multiple lines of prior treatment.